Evaluation of clinical and genetic factors in the population pharmacokinetics of carbamazepine.
Vincent L M YipHenry PertinezXiaoli MengJames L MaggsDaniel F CarrB Kevin ParkAnthony G MarsonDaniel F CarrPublished in: British journal of clinical pharmacology (2020)
Our data indicate that carbamazepine clearance was affected by total dose and phenytoin coadministration, but not by genetic factors, while carbamazepine 10,11-epoxide clearance was affected by a variant in the microsomal epoxide hydrolase gene. A much larger sample size would be required to fully evaluate the role of genetic variation in carbamazepine pharmacokinetics, and thereby predisposition to carbamazepine hypersensitivity.